<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is one of the major <z:hpo ids='HP_0002664'>neoplasms</z:hpo> and a leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> worldwide, and new preventive strategies are needed to lower the burden of this disease </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi>, a <z:chebi fb="0" ids="3095">biguanide</z:chebi>, which is widely used for treating <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, has recently been suggestive to have a suppressive effect on <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and <z:e sem="disease" ids="C1516170" disease_type="Neoplastic Process" abbrv="">cancer cell growth</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In a previous study conducted in non-diabetic subjects, we showed that oral short-term low-dose <z:chebi fb="0" ids="6801">metformin</z:chebi> suppressed the development of colorectal <z:mpath ids='MPATH_557'>aberrant crypt foci</z:mpath> (ACF) </plain></SENT>
<SENT sid="3" pm="."><plain>ACF have been considered as a useful surrogate biomarker of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, although the biological significance of these lesions remains controversial </plain></SENT>
<SENT sid="4" pm="."><plain>We devised a prospective randomized controlled trial to evaluate the chemopreventive effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> against metachronous colorectal <z:mpath ids='MPATH_491'>polyps</z:mpath> and the safety of this drug in non-diabetic post-polypectomy patients </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS/DESIGN: This study is a multi-center, double-blind, placebo-controlled, randomized controlled trial to be conducted in non-diabetic patients with a recent history of undergoing colorectal polypectomy </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> adult patients visiting the Yokohama City University hospital or affiliated hospitals for polypectomy shall be recruited for the study </plain></SENT>
<SENT sid="7" pm="."><plain>Eligible patients will then be allocated randomly into either one of two groups: the <z:chebi fb="0" ids="6801">metformin</z:chebi> group and the placebo group </plain></SENT>
<SENT sid="8" pm="."><plain>Patients in the <z:chebi fb="0" ids="6801">metformin</z:chebi> group shall receive oral <z:chebi fb="0" ids="6801">metformin</z:chebi> at 250 mg per day, and those in the placebo group shall receive an oral placebo tablet </plain></SENT>
<SENT sid="9" pm="."><plain>At the end of 1 year of administration of <z:chebi fb="0" ids="6801">metformin</z:chebi>/placebo, colonoscopy will be performed to evaluate the <z:mpath ids='MPATH_491'>polyp</z:mpath> formation </plain></SENT>
<SENT sid="10" pm="."><plain>DISCUSSION: This is the first study proposed to explore the effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> against colorectal <z:mpath ids='MPATH_491'>polyp</z:mpath> formation </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> activates AMPK, which inhibits the mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (mTOR) pathway </plain></SENT>
<SENT sid="12" pm="."><plain>The mTOR pathway plays an important role in the cellular protein translational machinery and cell proliferation </plain></SENT>
<SENT sid="13" pm="."><plain>Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> taking under treatment with <z:chebi fb="0" ids="6801">metformin</z:chebi> have been reported to be at a lower risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development than those not taking under treatment with <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="14" pm="."><plain>We showed in a previous study that <z:chebi fb="0" ids="6801">metformin</z:chebi> suppressed the formation of human colorectal ACF </plain></SENT>
<SENT sid="15" pm="."><plain>We therefore decided to conduct a study to determine whether <z:chebi fb="0" ids="6801">metformin</z:chebi> might suppress the formation of human colorectal <z:mpath ids='MPATH_491'>polyps</z:mpath> </plain></SENT>
<SENT sid="16" pm="."><plain>TRIAL REGISTRATION: This trial has been registered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry as UMIN000006254 </plain></SENT>
</text></document>